U.S. Markets closed
  • S&P 500

    4,109.31
    +58.48 (+1.44%)
     
  • Dow 30

    33,274.15
    +415.12 (+1.26%)
     
  • Nasdaq

    12,221.91
    +208.43 (+1.74%)
     
  • Russell 2000

    1,802.48
    +34.10 (+1.93%)
     
  • Crude Oil

    75.70
    +1.33 (+1.79%)
     
  • Gold

    1,987.00
    -10.70 (-0.54%)
     
  • Silver

    24.24
    +0.25 (+1.03%)
     
  • EUR/USD

    1.0847
    -0.0062 (-0.5640%)
     
  • 10-Yr Bond

    3.4940
    -0.0570 (-1.61%)
     
  • Vix

    18.70
    -0.32 (-1.68%)
     
  • GBP/USD

    1.2332
    -0.0058 (-0.4686%)
     
  • USD/JPY

    132.7970
    +0.1080 (+0.0814%)
     
  • BTC-USD

    28,356.41
    -53.97 (-0.19%)
     
  • CMC Crypto 200

    621.79
    +7.58 (+1.23%)
     
  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     
  • Nikkei 225

    28,041.48
    +258.55 (+0.93%)
     

Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'

  • Cantor Fitzgerald raised the price target on Abeona Therapeutics Inc (NASDAQ: ABEO) from $22 to $40 after adjusting the market model/ increasing the probability of success for EB-101.

  • Last week, the company reported topline data from the pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB).

  • The study met its two co-primary efficacy endpoints demonstrating statistically significant, clinically meaningful improvements in wound healing and pain reduction in large chronic RDEB wounds.

  • The analyst increased the probability of success from 70% to 85% to reflect the positive data and believes the data supporting EB-101 to become the standard of care for RDEB.

  • Cantor emphasizes its belief Abeona is the only company to now show positive pivotal data in RDEB when evaluating the larger, chronic wounds.

  • The positive data and capital raise of $35 million remove a financial overhang on the company, and investors can focus on the next step of potential commercialization, the analyst writes.

  • Price Action: ABEO shares are down 0.41% at $3.655 on the last check Tuesday.

  • Photo Via Company

Latest Ratings for ABEO

Date

Firm

Action

From

To

Nov 2021

SVB Leerink

Downgrades

Outperform

Market Perform

Nov 2021

HC Wainwright & Co.

Maintains

Buy

Jul 2021

HC Wainwright & Co.

Maintains

Buy

View More Analyst Ratings for ABEO

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.